Research Analysts’ Weekly Ratings Updates for iRhythm Technologies (IRTC)

iRhythm Technologies (NASDAQ: IRTC) recently received a number of ratings updates from brokerages and research firms:

• 6/2/2026 – iRhythm Technologies was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/1/2026 – iRhythm Technologies had its price target lowered by Canaccord Genuity Group Inc. from $180.00 to $152.00. They now have a “buy” rating on the stock.
• 6/1/2026 – iRhythm Technologies had its “buy” rating reaffirmed by HC Wainwright.
• 5/30/2026 – iRhythm Technologies was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/18/2026 – iRhythm Technologies had its price target lowered by Bank of America Corporation from $225.00 to $180.00. They now have a “buy” rating on the stock.
• 5/4/2026 – iRhythm Technologies had its price target raised by Citigroup Inc. from $155.00 to $157.00. They now have a “buy” rating on the stock.
• 5/3/2026 – iRhythm Technologies was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/1/2026 – iRhythm Technologies had its price target lowered by Canaccord Genuity Group Inc. from $198.00 to $180.00. They now have a “buy” rating on the stock.
• 5/1/2026 – iRhythm Technologies had its price target lowered by JPMorgan Chase & Co. from $215.00 to $175.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – iRhythm Technologies had its price target lowered by Wells Fargo & Company from $200.00 to $180.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – iRhythm Technologies had its price target raised by Needham & Company LLC from $254.00 to $255.00. They now have a “buy” rating on the stock.
• 4/25/2026 – iRhythm Technologies was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/21/2026 – iRhythm Technologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/15/2026 – iRhythm Technologies had its price target lowered by Truist Financial Corporation from $200.00 to $170.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar purchased 5,312 shares of iRhythm Technologies stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $10.71 per share, with a total value of $56,891.52. Following the acquisition, the director directly owned 25,611 shares of the company’s stock, valued at $274,293.81. This represents a 26.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.98% of the company’s stock.

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.